399 related articles for article (PubMed ID: 33301706)
21. Platelet-derived growth factor receptor β (PDGFRβ) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia.
Méhes G; Tzankov A; Hebeda K; Anagnostopoulos I; Krenács L; Bedekovics J
Histopathology; 2015 Nov; 67(5):617-24. PubMed ID: 25825163
[TBL] [Abstract][Full Text] [Related]
22. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN.
Gleitz HFE; Dugourd AJF; Leimkühler NB; Snoeren IAM; Fuchs SNR; Menzel S; Ziegler S; Kröger N; Triviai I; Büsche G; Kreipe H; Banjanin B; Pritchard JE; Hoogenboezem R; Bindels EM; Schumacher N; Rose-John S; Elf S; Saez-Rodriguez J; Kramann R; Schneider RK
Blood; 2020 Oct; 136(18):2051-2064. PubMed ID: 32726410
[TBL] [Abstract][Full Text] [Related]
23. Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion.
Tripodo C; Sangaletti S; Guarnotta C; Piccaluga PP; Cacciatore M; Giuliano M; Franco G; Chiodoni C; Sciandra M; Miotti S; Calvaruso G; Carè A; Florena AM; Scotlandi K; Orazi A; Pileri SA; Colombo MP
Blood; 2012 Oct; 120(17):3541-54. PubMed ID: 22955913
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms.
Vukotić M; Kapor S; Dragojević T; Đikić D; Mitrović Ajtić O; Diklić M; Subotički T; Živković E; Beleslin Čokić B; Vojvodić A; Santibáñez JF; Gotić M; Čokić VP
Exp Mol Med; 2022 Mar; 54(3):273-284. PubMed ID: 35288649
[TBL] [Abstract][Full Text] [Related]
25. Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis.
Wakahashi K; Minagawa K; Kawano Y; Kawano H; Suzuki T; Ishii S; Sada A; Asada N; Sato M; Kato S; Shide K; Shimoda K; Matsui T; Katayama Y
Blood; 2019 Apr; 133(15):1619-1629. PubMed ID: 30718230
[TBL] [Abstract][Full Text] [Related]
26. Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.
Martinaud C; Desterke C; Konopacki J; Vannucchi AM; Pieri L; Guglielmelli P; Dupriez B; Ianotto JC; Boutin L; Lataillade JJ; Le Bousse-Kerdilès MC
Genom Data; 2015 Sep; 5():1-2. PubMed ID: 26484208
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures.
Wong WJ; Baltay M; Getz A; Fuhrman K; Aster JC; Hasserjian RP; Pozdnyakova O
PLoS One; 2019; 14(5):e0216810. PubMed ID: 31071164
[TBL] [Abstract][Full Text] [Related]
28. [Pathomechanism and clinical impact of myelofibrosis in neoplastic diseases of the bone marrow].
Bedekovics J; Méhes G
Orv Hetil; 2014 Mar; 155(10):367-75. PubMed ID: 24583557
[TBL] [Abstract][Full Text] [Related]
29. Bone marrow microenvironment of MPN cells.
Malara A; Di Buduo CA; Abbonante V; Balduini A
Int Rev Cell Mol Biol; 2021; 365():71-96. PubMed ID: 34756245
[TBL] [Abstract][Full Text] [Related]
30. What is pre-fibrotic myelofibrosis and how should it be managed in 2018?
Curto-Garcia N; Ianotto JC; Harrison CN
Br J Haematol; 2018 Oct; 183(1):23-34. PubMed ID: 30328618
[TBL] [Abstract][Full Text] [Related]
31. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
Ramos TL; Sánchez-Abarca LI; Redondo A; Hernández-Hernández Á; Almeida AM; Puig N; Rodríguez C; Ortega R; Preciado S; Rico A; Muntión S; Porras JRG; Del Cañizo C; Sánchez-Guijo F
Oncotarget; 2017 Apr; 8(17):28187-28202. PubMed ID: 28390197
[TBL] [Abstract][Full Text] [Related]
32. Role of inflammation in the biology of myeloproliferative neoplasms.
Koschmieder S; Chatain N
Blood Rev; 2020 Jul; 42():100711. PubMed ID: 32505517
[TBL] [Abstract][Full Text] [Related]
33. Gli1
Schneider RK; Mullally A; Dugourd A; Peisker F; Hoogenboezem R; Van Strien PMH; Bindels EM; Heckl D; Büsche G; Fleck D; Müller-Newen G; Wongboonsin J; Ventura Ferreira M; Puelles VG; Saez-Rodriguez J; Ebert BL; Humphreys BD; Kramann R
Cell Stem Cell; 2017 Jun; 20(6):785-800.e8. PubMed ID: 28457748
[TBL] [Abstract][Full Text] [Related]
34. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
35. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
36. IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms.
Melo-Cardenas J; Bezavada L; Crawford JC; Gurbuxani S; Cotton A; Kang G; Gossett J; Marinaccio C; Weinberg R; Hoffman R; Migliaccio AR; Zheng Y; Derecka M; Rinaldi CR; Crispino JD
Blood; 2022 Dec; 140(26):2805-2817. PubMed ID: 36283106
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms.
Boiocchi L; Hasserjian RP; Pozdnyakova O; Wong WJ; Lennerz JK; Le LP; Dias-Santagata D; Iafrate AJ; Hobbs GS; Nardi V
Hum Pathol; 2019 Apr; 86():1-11. PubMed ID: 30594750
[TBL] [Abstract][Full Text] [Related]
38. From cell to cell: Identification of actionable targets in bone marrow fibrosis using single-cell technologies.
Leimkühler NB; Costa IG; Schneider RK
Exp Hematol; 2021 Dec; 104():48-54. PubMed ID: 34601067
[TBL] [Abstract][Full Text] [Related]
39. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
40. The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis.
Kramann R; Schneider RK
Blood; 2018 May; 131(19):2111-2119. PubMed ID: 29572380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
